Clinical Trial: An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07598578) titled 'An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.' on May 13.

Brief Summary: An Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Peripheral T-Cell Lymphoma Refractory

Intervention: DRUG: Azacitidine (AZA)

Azacitidine 100 mg is administered subcutaneously once dail...